As of Wednesday close, Allogene Therapeutics Inc.’s (NASDAQ:ALLO) stock was down -$0.08, moving down -1.96 percent to $4.00. The average number of shares traded per day over the past five days has been 1,558,520 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.34 fall in that time frame. In the last twenty days, the average volume was 2,218,675, while in the previous 50 days, it was 2,921,014.
Since last month, ALLO stock retreated -24.81%. Shares of the company fell to $3.89 on 08/14/23, the lowest level in the past month. A 52-week high of $17.23 was reached on 01/27/23 after having rallying from a 52-week low of $3.89. Since the beginning of this year, ALLO’s stock price has dropped by -36.41% or -$2.29, and marked a new high 7 times. However, the stock has declined by -76.78% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
ALLO stock investors should be aware that Allogene Therapeutics Inc. (ALLO) stock had its last reported insider trading activity 10 days ago on Aug 07. Mayo Stephen, the Director of the company, disposed of 10,000 shares for $4.29 on Aug 07. It resulted in a $42,855 divestment by the insider. Bhavnagri Veer sold 3,000 shares at an average price of $6.85 on Feb 13. The insider now owns 577,677 shares following the transaction. On Jan 17, General Counsel Bhavnagri Veer sold 3,000 shares at $7.04 apiece. The transaction was valued at $21,120.
Valuation Metrics
The stock’s beta is 0.77. Besides these, the trailing price-to-sales (P/S) ratio of 3360.40, the price-to-book (PB) ratio of 0.94.
Financial Health
In the three months ended June 29, Allogene Therapeutics Inc.’s quick ratio stood at 9.20, while its current ratio was 9.20, showing that the company is able to pay off its debt. Based on annual data, ALLO earned $335.69 million in gross profit and brought in $0.24 million in revenue.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ALLO’s revenue fell -125.0% during the quarter, while net income inched up to $40000.0. While analysts expected Allogene Therapeutics Inc. to report -$0.59 quarterly earnings, the actual figure was -$0.53 per share, beating the consensus estimate by 10.20%. During the quarter, the company generated -$77.95 million in EBITDA. The liabilities of Allogene Therapeutics Inc. were 148.06 million at the end of its most recent quarter ended June 29, and its total debt was $98.2 million. The value of shareholders’ equity is $167.63 million.
Technical Picture
This quick technical analysis looks at Allogene Therapeutics Inc.’s (ALLO) price momentum. With a historical volatility rate of 64.18%, the RSI 9-day stood at 30.45% on 16 August.
With respect to its five-day moving average, the current Allogene Therapeutics Inc. price is down by -7.83% percent or -$0.34. At present, ALLO shares trade -26.06% below its 20-day simple moving average and -20.79% percent below its 100-day simple moving average. However, the stock is currently trading approximately -28.19% below its SMA50 and -60.90% below its SMA200.
Stochastic coefficient K was 11.84% and Stochastic coefficient D was 11.00%, while ATR was 0.29. Given the Stochastic reading of 7.24% for the 14-day period, the RSI (14) reading has been calculated as 34.79%. As of today, the MACD Oscillator reading stands at -0.18, while the 14-day reading stands at -0.41.
Analyst Ratings
Allogene Therapeutics Inc. (ALLO) has been rated Overweight by analysts. According to 0 brokerage firms, ALLO is a sell, and 3 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate Allogene Therapeutics Inc. stock as buy, with 14 recommending it as overweight.
With a median target price of $15.00, the current consensus forecast for the stock is $5.00 – $35.00. Based on these forecasts, analysts predict Allogene Therapeutics Inc. (ALLO) will achieve an average price target of $16.13.
